Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2a Clinical Trial to Evaluate the Safety and Efficacy of EN001 in Patients With Charcot-Marie-Tooth Disease Type 1A(CMT1A) (Phase 1b: Open-label, Dose-escalation, Single-center; Phase 2a: Randomized, Double-blind, Placebo-controlled, Multicenter)

NCT06328712 is registered in ClinicalTrials.gov with ENCell as lead sponsor.

NCT NCT06328712
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06328712 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2a Clinical Trial to Evaluate the Safety and Efficacy of EN001 in Patients With Charcot-Marie-Tooth Disease Type 1A(CMT1A) (Phase 1b: Open-label, Dose-escalation, Single-center; Phase 2a: Randomized, Double-blind, Placebo-controlled, Multicenter)
Lead sponsor
ENCell
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 30, 2024
Completion date
December 31, 2026
Enrollment
27 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

charcot-marie-tooth disease type 1a